Peter Ashley Marks, Director at Alterity Therapeutics, bought ATHE on Aug 31, 2026
Data as of Oct 16
- Traded
- Aug 31, 2026
- Disclosed
- Sep 8, 2026
- Filed
- 8 days after the trade · late
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
ATHE since disclosure
−41.9%
Similar stocks (XLV) since disclosure
+5.7%
XLV — its sector index fund
Change in closing price from Sep 8, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.